Novartis Zelmac Co-Promotion Is Possibility, Firm Indicates
Novartis may consider a co-promotion partner for the irritable bowel syndrome therapy Zelmac (tegaserod) in the U.S., CEO Daniel Vasella indicated during an Aug. 21 conference call with analysts.
You may also be interested in...
Novartis' latest trial for the irritable bowel syndrome agent Zelmac focuses on a 12 mg daily dosing regimen in 1,500 females, with results to be submitted to FDA by the end of the year.
Novartis Pharmaceutical U.S. Chief Operating Officer David Epstein will head the Swiss company's new global oncology business unit effective Sept. 1.
Novartis is eliminating the 8 mg Zometa arm of its ongoing bone metastases studies, following the detection of elevated serum creatinine levels in some patients.